摘要
不断上升的抗生素抵抗出现促使寻找新的策略去抵御那些对宿主产生持续感染的微生物。对抗生素的耐受性、缓慢复制的细菌经常导致潜在的和长久的感染,这就是药物治疗中最大的挑战。在长久的呆在宿主体内需要一个较大的重构病原体代谢功能,因为它们要面对的是极其敌对的环境。因而,针对关键的代谢功能能够导致更好的抗生素治疗,缩短潜伏周期,并且相比传统的抗生素有更强的敏感性。细菌,不同于哺乳动物,将无机元素硫吸收进半胱氨酸,这是许多关键代谢物的先导物质,包括还原剂、辅酶因子和膜成分。抑制半胱氨酸的生物合成被证实能严重地干扰病原体抵抗氧化应激,感染宿主和构建长期的感染的活性。这篇综述有以下几个目的:(1)简要的阐述在硫同化中转运子和酶的关键结构和功能性质;(2)提供生物上的证据以支持该通路的开发以确定潜在的靶标;(3)强调在寻找有前景的候选药物以开发新的化合物以增强抗生素治疗的显著效果和进展。
关键词: 抗生素耐药性,抗生素,半胱氨酸生物合成,结核杆菌,乙酰丝氨酸巰解酶,还原性的硫同化通路,硫新陈代谢。
Current Medicinal Chemistry
Title:Inhibitors of the Sulfur Assimilation Pathway in Bacterial Pathogens as Enhancers of Antibiotic Therapy
Volume: 22 Issue: 2
Author(s): Barbara Campanini, Marco Pieroni, Samanta Raboni, Stefano Bettati, Roberto Benoni, Chiara Pecchini, Gabriele Costantino and Andrea Mozzarelli
Affiliation:
关键词: 抗生素耐药性,抗生素,半胱氨酸生物合成,结核杆菌,乙酰丝氨酸巰解酶,还原性的硫同化通路,硫新陈代谢。
摘要: The rising emergence of antibiotic resistance urges the search for new strategies to defeat microorganisms that lead to persistent infections of the host. Tolerant to antibiotics, slowly replicating bacteria often cause latent and persistent infections that are the most challenging for pharmacological treatment. Persistence inside the host requires an extensive re-programming of the pathogen metabolic functions, due to the extremely hostile environment they face. Therefore, targeting key metabolic functions could result in better antibiotic treatments, shortened latency periods, and increased susceptibility to traditional antibiotics. Bacteria, differently from mammals, assimilate inorganic sulfur into cysteine, the precursor of a number of key metabolites including reducing agents, cofactors and membrane components. Inhibition of cysteine biosynthesis was proven to interfere heavily with the ability of pathogens to fight oxidative stress, to infect the host and to establish long-term infections. This review has the purpose of i) briefly summarizing the key structural and functional properties of transporters and enzymes involved in sulfur assimilation, ii) presenting biological evidence that supports the exploitation of this pathway for the identification of potential targets and, iii) highlighting intense efforts and advancements in the search of promising candidates for the development of novel compounds that enhance antibiotics therapy.
Export Options
About this article
Cite this article as:
Barbara Campanini , Marco Pieroni , Samanta Raboni , Stefano Bettati , Roberto Benoni , Chiara Pecchini , Gabriele Costantino and Andrea Mozzarelli , Inhibitors of the Sulfur Assimilation Pathway in Bacterial Pathogens as Enhancers of Antibiotic Therapy, Current Medicinal Chemistry 2015; 22 (2) . https://dx.doi.org/10.2174/0929867321666141112122553
DOI https://dx.doi.org/10.2174/0929867321666141112122553 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design New Insights into the Modulation of Immune Response by Fasciola hepatica Excretory-Secretory Products
Current Immunology Reviews (Discontinued) Bipolar Disorder: The Role of the Kynurenine and Melatonergic Pathways
Current Pharmaceutical Design Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
Recent Patents on DNA & Gene Sequences The Role of Epithelial-Mesenchymal Interactions in Tissue Repair, Fibrogenesis and Carcinogenesis
Current Signal Transduction Therapy Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Current Pharmacogenomics and Personalized Medicine Macrophage Migration Inhibitory Factor: A Therapeutic Target Across Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Potential Contribution of Action of Renin Angiotensin System to Bone Metabolism
Current Hypertension Reviews A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design HRV Signaling in Airway Epithelial Cells Is Regulated by ITAM-Mediated Recruitment and Activation of Syk
Protein & Peptide Letters Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis
Current Bioactive Compounds Editorial [Hot Topic: Pathophysiology and Current Therapeutics of Inflammatory Diseases (Guest Editor: Fadia R. Homaidan)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Early Prediction of Preeclampsia: Hope for Early Intervention?
Current Women`s Health Reviews Oxidative Stress in Autoimmune Diseases: An Under Dealt Malice
Current Protein & Peptide Science Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?
Current Molecular Pharmacology